Chinese investment firm Decheng Capital has led a US$30 million series C round in Nanjing-based pharmaceutical firm Impact Therapeutics. Existing investor Lilly Asia Ventures also participated in the round, according to Impact Therapeutics’ announcement. Impact Therapeutics focuses on the discovery, development and commercialization of therapeutics to treat cancer and other life threatening diseases. With several anti-tumor drug projects in preclinical and clinical stages, it has submitted a class 1.1 drug investigational new drug (IND) application in 2015. PARP inhibitors are …

Decheng Capital Leads $30M Series C Round In China’s Impact Therapeutics appeared first on China Money Network.


Visit the original source and full text: China Money Network